Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the BREVACTA study of RoACTEMRA (tocilizumab, known as ACTEMRA outside Europe) given as a subcutaneous (SC) injection to patients with rheumatoid arthritis (RA) met its primary endpoint.

Amgen (NASDAQ:AMGN) announced financial results for the second quarter of 2012. Key results for the quarter include: Total revenues increased 13 percent to $4,477 million, with 8 percent product sales growth driven by strong performance across the portfolio;

AstraZeneca revenue for the second quarter was $6,660 million, down 18 percent at constant exchange rates (CER). Revenue declined by 21 percent on an actual basis as a result of the negative impact of exchange rate movements.

Eli Lilly and Company (NYSE: LLY) today announced financial results for the second quarter of 2012: Worldwide revenue declined 10 percent to $5.6 billion, driven by Zyprexa patent expirations, partially offset by significant growth in other products;

Pfizer Inc. (NYSE: PFE) announced today that top-line results for Lyrica® (pregabalin) capsules CV Study A0081104 - Assessment of the Impact of Lyrica on Sperm Production in Healthy Volunteers - demonstrate that Lyrica does not affect the reproductive function in healthy males when compared to placebo.

The US Food and Drug Administration (FDA) has approved Afinitor® (everolimus) tablets* (approval represents the first major advance for US patients with advanced HR+ breast cancer since aromatase inhibitors were introduced more than 15 years ago[1])

Group net sales reached USD 14.3 billion (-4%, +1% cc) in the second quarter, with growth from recently launched products more than offsetting the loss associated with the Diovan patent expiration.